Usually the wild type of glioma is more dangerous than the mutant type, and patients are advised to seek prompt medical attention, medication, and surgery. The isocitrate dehydrogenase gene (IDH) in the molecular test for gliomas can divide imaging similar gliomas into two completely different types, IDH wild type and IDH mutant type. IDH wild-type means that the IDH gene is normal, but it does not mean that the tumor is benign, and patients with this type of glioma will have many genomic alterations in their tumors. With the exception of hairy cell astrocytoma, the prognosis for most patients with IDH wild-type gliomas is very poor. IDH-mutant gliomas have changes in the IDH gene within the tumor that can produce an abnormal metabolite called 2-HG, which further alters the methylation status of the genome and leads to tumorigenesis. the prognosis for IDH-mutant gliomas is generally better than that for wild-type. It is not possible to generalize which glioma is more dangerous, the mutant type or the wild type.